SEC Filings

Filing Description Date Filed Sorted Descending Size  
CT ORDER confidential treatment order 01-19-2012 7.2 KB  
4 eshelman, fredric n 12-22-2011 26.7 KB  
4 eshelman, fredric n 12-19-2011 27.5 KB  
SC 13D/A amended general statement of beneficial ownership 12-15-2011 38.3 KB  
4 eshelman, fredric n 12-15-2011 28.2 KB  
8-K current report 12-13-2011 38.3 KB  
4/A kaldor stephen w 12-07-2011 25.8 KB  
4/A corr peter b 12-07-2011 25.5 KB  
4/A dixon wendy l 12-07-2011 25.5 KB  
4/A ruscher robert p 12-07-2011 25.7 KB  
4 bondurant, stuart 12-07-2011 27.9 KB  
4/A bondurant stuart 12-07-2011 25.5 KB  
4 covington, paul s 12-07-2011 27.8 KB  
SC 13D/A amended general statement of beneficial ownership 12-05-2011 38.7 KB  
4 eshelman, fredric n 12-05-2011 28.8 KB  
4 eshelman, fredric n 11-28-2011 27.9 KB  
4 eshelman, fredric n 11-22-2011 28.2 KB  
4 mcintyre, gail frances 11-21-2011 28.0 KB  
8-K current report 11-18-2011 48.6 KB  
SC 13D/A amended general statement of beneficial ownership 11-15-2011 38.5 KB  
Showing 1-20 of 116 Page: 1 2 3 ... 6  Next 20
Investor Relations
Contact:

Sailash Patel
Vice President, Strategic Development
Furiex Pharmaceuticals, Inc.
+1 919 456 7814